MSH3 Knockout Cell Line (HEK293)

The choice depends on whether you are studying MSH3's role as a MutS family member specialized for larger insertion-deletion loops or modeling its role in trinucleotide repeat expansion disorders. The Knockout line is the standard tool for asking whether MSH3 is required for these activities — MSH3 partners with MSH2 to form MutSβ, which recognizes 2-13 nucleotide insertion-deletion loops, complementing MutSα's preference for small mismatches. MSH3 has been identified as a key driver of somatic CAG repeat expansion in Huntington's disease and other trinucleotide repeat disorders. Overexpression is useful for studying MSH3 in heterologous expression contexts. For DNA repair and repeat expansion research, the EDITGENE MSH3 Knockout in HEK293 is highly informative — MSH3 has emerged as a major therapeutic target for Huntington's disease because MSH3 loss prevents somatic CAG expansion, which drives disease onset. Rescue with wild-type or ATPase-deficient MSH3 enables structure-function studies. The knockout is valuable for studying MSH3-targeted therapeutic approaches in Huntington's disease and other repeat expansion disorders. MSH3 inactivation is also relevant for cancer with elevated EMAST (elevated microsatellite alterations at selected tetranucleotide repeats).

Primary applications: • Trinucleotide repeat stability: CAG/CTG repeat instability assays in HD-relevant or other repeat disorder contexts — MSH3 loss prevents somatic CAG expansion that drives HD onset. • Huntington's disease modeling: rescue with wild-type MSH3 in HD-relevant contexts to study somatic instability mechanisms. • MSH3-targeted therapeutic mechanism: critical genetic control for MSH3-lowering ASOs and small molecules being developed for HD (Annexon, others). • EMAST and cancer biology: tetranucleotide repeat instability analysis given MSH3's role in EMAST-positive cancers. EDITGENE recommends this model for researchers investigating MSH3 biology, trinucleotide repeat expansion disorders, and MSH3-targeted Huntington's disease therapeutics.

Yes. MSH3 rescue experiments are well-established for repeat expansion research: • Construct design: use a codon-modified MSH3 sequence with a small C-terminal tag (FLAG, HA). MSH3 has the canonical MutS family architecture — preserve all elements. • ATPase-deficient rescue: ATP-binding lysine mutation abolishes catalytic activity and serves as the standard specificity control. • MSH2 partnership: MSH3 requires MSH2 for stability and MutSβ formation — rescue interpretation considers MSH2 expression. • Huntington's disease relevance: rescue with wild-type MSH3 in HD-relevant contexts can quantify the contribution of MSH3 to somatic CAG expansion. • Functional readout: rescue should restore loop-out structure recognition and trinucleotide repeat-related MMR activities. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.